Case of psoriatic arthritis mutilans whose finger dysfunction was successfully ameliorated by surgical intervention during infliximab treatment

2018 ◽  
Vol 45 (3) ◽  
pp. e61-e62
Author(s):  
Yuka Kunimi ◽  
Monji Koga ◽  
Takuya Ishibashi ◽  
Yoshitsugu Tanaka ◽  
Takuaki Yamamoto ◽  
...  
2015 ◽  
Vol 4 (7) ◽  
pp. 205846011558809 ◽  
Author(s):  
Leena Laasonen ◽  
Björn Guðbjörnsson ◽  
Leif Ejstrup ◽  
Lars Iversen ◽  
Thomas Ternowitz ◽  
...  

Psoriatic arthritis mutilans (PAM) is the most severe and rare form of psoriatic arthritis (PsA). We describe radiological development in a typical case of PAM covering three decades in order to elucidate the need for early diagnosis of PAM. Radiographs of hands and feet, taken from 1981 to 2010, were evaluated using the Psoriatic Arthritis Ratingen Score (PARS). When PsA was diagnosed, in 1981, gross deformity was observed in the second PIP joint of the left foot. Several pencil-in-cup deformities and gross osteolysis were present in the feet in the first decade of the disease. Over 10 years, many joints had reached maximum scores. During the follow-up, other joints became involved and the disease developed clinically. Reporting early signs suggestive of PAM, e.g. pencil-in cup deformities and gross osteolysis in any joint, should be mandatory and crucial. This would heighten our awareness of PAM, accelerate the diagnosis, and lead to improved effective treatment in order to minimize joint damages resulting in PAM.


2006 ◽  
Vol 26 (7) ◽  
pp. 1132-1133 ◽  
Author(s):  
Grigorios T. Sakellariou ◽  
Periklis Vounotrypidis ◽  
Charalampos Berberidis

2013 ◽  
Vol 40 (8) ◽  
pp. 1419-1422 ◽  
Author(s):  
Vinod Chandran ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell ◽  
Björn Gudbjörnsson

Arthritis mutilans is often described as the most severe form of psoriatic arthritis. However, a widely agreed on definition of the disease has not been developed. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members hoped to agree on a definition of arthritis mutilans and thus facilitate clinical and molecular epidemiological research into the disease. Members discussed the clinical features of arthritis mutilans and definitions used by researchers to date; reviewed data from the ClASsification for Psoriatic ARthritis study, the Nordic psoriatic arthritis mutilans study, and the results of a premeeting survey; and participated in breakout group discussions. Through this exercise, GRAPPA members developed a broad consensus on the features of arthritis mutilans, which will help us develop a GRAPPA-endorsed definition of arthritis mutilans.


2017 ◽  
Vol 9 (2) ◽  
pp. 26-29 ◽  
Author(s):  
Yuki Matsuura-Otsuki ◽  
Takaaki Hanafusa ◽  
Hiroo Yokozeki ◽  
Kyoko Watanabe

A 42-year-old Japanese man presented with persistent headache during treatment for psoriatic arthritis (PsA) with infliximab. Treatment with infliximab was initiated 3 years before and the psoriatic skin lesions with arthritis were well controlled. However, after 21 doses of infliximab, the skin lesions and joint pain exacerbated and became intractable. Ten days after the dosage of infliximab was increased, the patient experienced headache and nausea with high fever. He had scaly, well-circumscribed erythemas on his trunk, extremities, and deformed nails. He also had swelling and pain in multiple joints. His complete blood and differential leukocyte counts were normal. The level of C-reactive protein was 16.66 mg/dL, whereas anti-infliximab antibodies were absent. Nuchal rigidity was absent and there were no abnormal neurological findings; however, jolt test results were positive. Results from magnetic resonance imaging were normal, whereas those from cerebrospinal fluid (CSF) examination were almost normal. The CSF contained mononuclear cells and was negative for bacteriological cultures, India ink staining, and polymerase chain reaction amplification of herpesvirus group DNA. Headache and nausea improved 2 months after infliximab was discontinued. The patient failed to respond to infliximab treatment for PsA, and we diagnosed infliximab-induced aseptic meningitis. Infliximab was discontinued and treatment with ustekinumab and methotrexate was initiated. Thereafter, the psoriatic skin lesion and joint pain gradually improved. Infliximab-induced aseptic meningitis may be a differential diagnosis when symptoms of meningitis develop during infliximab administration.


2013 ◽  
Vol 42 (5) ◽  
pp. 373-378 ◽  
Author(s):  
B Gudbjornsson ◽  
L Ejstrup ◽  
JT Gran ◽  
L Iversen ◽  
U Lindqvist ◽  
...  

2013 ◽  
Vol 40 (7) ◽  
pp. 1233-1236 ◽  
Author(s):  
VINCENZO BRUZZESE ◽  
CINZIA MARRESE ◽  
LORENZO RIDOLA ◽  
ANGELO ZULLO

2007 ◽  
Vol 13a (1) ◽  
pp. 21-27 ◽  
Author(s):  
Kristian Reich ◽  
Alan Menter ◽  
Michael Plotnick ◽  
Cynthia Guzzo ◽  
Shu Li ◽  
...  

Background To assess the consistency of infliximab (Remicade) response among different subgroups of patients with moderate to severe psoriasis, the impact of gender, obesity, age, baseline psoriasis severity, concomitant psoriatic arthritis (PsA), or prior therapies on response to infliximab was studied in an integrated efficacy analysis. Methods Data from three randomized, placebo-controlled clinical trials (SPIRIT, EXPRESS and EXPRESS II) that evaluated the use of infliximab in patients with moderate to severe psoriasis were included in this integrated analysis. Patients received placebo, infliximab 3 mg/kg, or infliximab 5 mg/kg at 0, 2 and 6 wks. The common primary end point at week 10 was the proportion of patients achieving ≥75% improvement in the Psoriasis Area and Severity Index (PASI 75) from baseline. Safety data through week 16 were pooled for analysis. Results Of the 1,462 patients included in this analysis, 70.6% and 79.3% in the infliximab 3 and 5 mg/kg groups, respectively, achieved at least a PASI 75 response at week 10, compared with 2.7% in the placebo group (both p<0.001). The proportions of patients achieving PASI 75 at week 10 were consistent in subgroups defined by baseline demographic characteristics (gender, age, body mass index) and also defined by baseline disease characteristics (PASI severity, body surface area, presence of psoriatic arthritis). Consistent results were also observed regardless of psoriasis therapeutic history. Infliximab treatment was generally well-tolerated by the majority of study participants. Conclusion A consistently high level of clinical response to infliximab was demonstrated across subgroups defined by a variety of baseline demographic and disease characteristics in patients with psoriasis. Infliximab was similarly effective regardless of previous use of phototherapy or major conventional systemic therapies.


1988 ◽  
Vol 13 (4) ◽  
pp. 510-515 ◽  
Author(s):  
Robert L. Walton ◽  
Richard E. Brown ◽  
David F. Giansiracusa

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Ritsuko Saito ◽  
Ernest Wong

Abstract Case report - Introduction Granulomatous disorders are diverse in their aetiologies and presentations. We present an unusual case of severe psoriatic arthritis patient who subsequently developed multiple granulomatous diseases over time, granulomatous interstitial nephritis, granulomatous sarcoidosis with hilar lymphadenopathy and localised laryngeal granulomatous inflammation secondary to lambda type amyloidosis. Case report - Case description 52-year-old gentleman with arthritis mutilans secondary to severe poorly controlled psoriatic arthritis was followed up in Rheumatology clinic. Earlier therapy with leflunomide and methotrexate provided inadequate control. Golimumab, despite giving a good response, was stopped in 2013 after 5 months of treatment due to acute kidney injury. Renal biopsy revealed granulomatous interstitial nephritis, thought to be Golimumab-induced based on the timing of usage and reversibility with discontinuation. He was then trialled on Ustekinumab and Secukinumab in 2016 and 2017 respectively with variable response. He also had a few-years history of voice change (high pitched) and sore throat which he attributed to recurrent colds. He denied dysphagia or breathlessness, and he did not have stridor. He has never smoked and only drank alcohol occasionally. ENT team noted white deposits on erythematous and thickened false vocal cords and posterior glottis with a thin web on microlaryngoscopy, which histologically proved to show granulomatous inflammation, potentially consisting of amyloid, although congo red stain was negative. On further investigation, including SAP scan, he was diagnosed with localised lambda type amyloid. Increasing throat pain and worsening dysphonia prompted change of management from conservative to a surgery at a specialist centre and an input from speech and language therapy team. During this time, consideration for Etanercept for his joint and skin disease was put on hold, pending further management of laryngeal amyloidosis. Furthermore, he presented to hospital with breathlessness in 2019, where his chest X-ray showed bulky right hilum and a follow-up CT chest revealed calcified right hilar and mediastinal lymphadenopathy, ground glass opacification and consolidation. Histology from hilar node was suggestive of sarcoidosis, with stain negative for amyloid. He underwent removal of false vocal cords for his symptomatic laryngeal amyloidosis. He continues to be followed up at the local Rheumatology, Dermatology and ENT team. Case report - Discussion Granulomatous diseases have vast aetiologies, including infectious, immunological, neoplastic, and chemical-induced processes. The age at which they affect patients and tissue they involve also vary hugely. This is the first reported case of three seemingly unrelated granulomatous diseases occurring in a single patient with severe refractory psoriatic arthritis. Retrospective reassessment of the histology samples supported that these are three separate pathologies. It is very unusual for one patient to acquire multiple separate granulomatous diseases, which was why the diagnostic process of this patient was challenging. In this case, managing the original underlying psoriatic arthritis was particularly difficult due to interruptions of treatment for adverse drug effects and investigations and treatment of subsequent granulomatous diseases. The case also raises questions about possible currently unknown association between the pathologies. Case report - Key learning points Key points are the uniqueness of this case and that it highlighted the possibility of currently under-reported association between these three granulomatous conditions. As ever, a multidisciplinary approach to managing such a complex patient is important for the provision of good care.


Sign in / Sign up

Export Citation Format

Share Document